Ultrasonic mediated synthesis of monodispersed lanthanum hydroxide nanorods for possible bioimplant application.
Harini D., Rajaram A., Rajaram R.
Prospective Study, published in J Mater Sci Mater Med (2015) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- J Mater Sci Mater Med (2015)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 25601669
- DOI
- 10.1007/s10856-015-5378-6
- Citations
- 1
Abstract (original English)
Monodispersed lanthanum hydroxide nano-rods (LaNRs) were synthesized for prospective biomedical application using a microwave heating and ultrasonic agitation methodology which does not require any toxic stabilizing agent. The average length and diameter of the LaNRs thus obtained were 183.4 ± 3.6 and 9.9 ± 0.2 nm respectively, as analyzed by HRTEM. FTIR spectrum confirmed the presence of OH groups. The thermal transformation of lanthanum hydroxide (La(OH)3) was studied by thermogravimetric analysis. The synthesized LaNRs were found to be stable for a period of 1 month at room temperature. They were biocompatible as evaluated by haemocompatibility assay and viability assay using human peripheral blood mononuclear cells. The pro-angiogenic property of LaNRs was demonstrated by in vivo chick chorioallantoic membrane assay. The LaNRs induced osteoblast differentiation of human adipose derived stem cells with significant calcium (Ca(2+)) deposition indicating potential applications in bone tissue engineering.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.